Stocktoria

Kyverna Therapeutics, Inc. KYTX

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-08

Kyverna Therapeutics, Inc. statistics & valuation

Market cap$513.1M
P / B2.2×
Return on equity-69.4%
Net cash$99.3M
Enterprise value USD$413.8M
Earnings yield EBIT/EV-41%
Return on capital-66%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-47.80% -69.40% 202320242025
Shares outstanding
1.3M 43.2M 60.4M 202320242025
Net debt ($)
-$99.3M 202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-80.30% -41.80% -54.90% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
0.11× 202320242025
EPS ($)
-$89.61 -$3.33 -$3.64 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-54.9%-41.8%-80.3%
Return on equity-69.4%-47.8%459.4%
Debt / equity0.11×——
Current ratio7.758.613.05

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.